Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.
about
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyLower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.Investigational VEGF antagonists for psoriasis.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.Pazopanib: a review of its use in the management of advanced renal cell carcinoma.Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials.Immune effects of bevacizumab: killing two birds with one stoneA network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer.Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE.Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
P2860
Q26744087-0718D1B9-ADA5-4012-9B7C-4937CE9CD72BQ30831967-3FDEC7A8-4000-489A-B32B-CBBD3C836400Q34105997-0A88D694-CEEE-4102-9AE1-1A9E5CE512B7Q34351372-9FC1F74B-1493-4C35-804E-147F2AD1440BQ36287965-08C5FA30-A112-43BA-B3FE-864C1B99D767Q37956733-60A2AFA3-7CCD-4E18-8FA6-A09285AF711BQ38068584-4D596CB1-4E31-46C3-8EFC-F225D1B24127Q38110320-1C4452E1-97A0-4724-9CDD-05EB66B44841Q38163976-73E0ABEF-AFDC-46DB-8DE9-C9379BB18FC6Q38220728-C9290E94-CA32-47D7-B7E3-8C1CE6DB1A6FQ39668468-A58DBFE1-E095-4FF9-9386-0E2D54BCAC71Q41401879-9B8F16A8-BC55-4995-B910-BFC8EC057468Q47143379-927563B9-0F8D-4E1A-A8BF-3DB396ED47BDQ47744121-436194C0-46DB-477E-BA9F-FC7BD758D58FQ51289585-D4F4425A-74E9-4CFC-AF51-EFD9F853BAFCQ51817159-B03B7AD4-8B74-4475-8155-AFD4DB1FF1DAQ54109642-92FBF3CB-C749-425B-B918-EA39F33FFF03
P2860
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@en
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@nl
type
label
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@en
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@nl
prefLabel
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@en
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@nl
P2860
P1433
P1476
Vascular endothelial growth fa ...... tment of renal cell carcinoma.
@en
P2093
Laurence Albiges
P2860
P304
P356
10.2165/11591410-000000000-00000
P577
2011-06-01T00:00:00Z
P6179
1012210710